Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

Core Insights - Pelthos Therapeutics Inc. reported a significant growth in net product revenue for ZELSUVMI, achieving $9.1 million in the fourth quarter of 2025, which is a 28% increase from the previous quarter [1][8] - The total net product revenue for ZELSUVMI from its launch in July 2025 through December 31, 2025, reached $16.2 million, contributing to a total revenue of $16.8 million for the year [1][4] Revenue and Sales Performance - A total of 8,948 ZELSUVMI units were prescribed by 2,712 unique prescribers in fiscal year 2025, with a remarkable 129% quarter-over-quarter increase in units dispensed from 2,716 in Q3 2025 to 6,232 in Q4 2025 [2][4] - The company anticipates continued strong growth for ZELSUVMI in 2026, supported by recent capital raises and acquisitions [5] Financial Overview - The cost of goods sold for the fourth quarter of 2025 was $1.7 million, down from $2.3 million in the third quarter, indicating improved cost management [8] - Selling, general, and administrative (SG&A) expenses decreased from $19.6 million in Q3 2025 to $18.5 million in Q4 2025, reflecting a 6% reduction [8] - The operating loss improved from approximately $15.4 million in Q3 2025 to $12.0 million in Q4 2025, indicating progress towards positive cash flow [8] Strategic Acquisitions - In November 2025, Pelthos completed the acquisition of XEPI®, a topical treatment for impetigo, which addresses a significant unmet need in pediatric care [4][5] - The company also announced the acquisition of XEGLYZE® in January 2026, a treatment for head lice, further expanding its portfolio in pediatric infectious diseases [4][5] Capital and Financing - Pelthos raised $18.0 million through private convertible notes financing in November 2025, which facilitated the acquisition of XEPI and supported the commercial rollout of ZELSUVMI [4][5] - In January 2026, the company secured a $50.0 million senior secured term loan facility, drawing $30.0 million at closing, enhancing its financial flexibility [4][5] Market Position and Future Outlook - The company is well-positioned to capitalize on large addressable markets with its three products: ZELSUVMI, XEPI, and XEGLYZE, which target similar pediatric demographics [5] - The expansion of the sales force, adding 14 representatives, aims to enhance market penetration and revenue growth [4][5]